Edition:
United States

pSivida Corp (PSDV.OQ)

PSDV.OQ on NASDAQ Stock Exchange Global Market

1.06USD
14 Dec 2017
Change (% chg)

$-0.09 (-7.83%)
Prev Close
$1.15
Open
$1.20
Day's High
$1.20
Day's Low
$1.03
Volume
171,912
Avg. Vol
68,705
52-wk High
$2.45
52-wk Low
$1.03

Latest Key Developments (Source: Significant Developments)

pSivida reports Q1 loss per share of $0.15
Tuesday, 7 Nov 2017 06:00am EST 

Nov 7 (Reuters) - pSivida Corp ::Q1 loss per share $0.15.Q1 revenue $385,000 versus $277,000.Q1 revenue view $640,000 -- Thomson Reuters I/B/E/S.Q1 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.  Full Article

Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​
Tuesday, 10 Oct 2017 01:31am EDT 

Oct 10 (Reuters) - Nicox SA :Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​.Would make additional payments for any incremental development activities for each implant formulation product candidate.Expected payments from Nicox associated with agreement are not considered material to Nicox's financial statements at this time​.Says ‍pSivida will be responsible for initial development activities of ocular insert formulations, for which it will receive undisclosed sums​.  Full Article

Nicox and pSivida enter strategic collaboration agreement
Tuesday, 10 Oct 2017 01:30am EDT 

Oct 10 (Reuters) - NICOX SA ::REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA.NEW INTELLECTUAL PROPERTY FROM THE COLLABORATION RELATING TO THE DRUG-DEVICE COMBINATION WILL BE JOINTLY OWNED‍​.PSIVIDA TO BE RESPONSIBLE FOR INITIAL DEVELOPMENT ACTIVITIES OF OCULAR INSERT FORMULATIONS, FOR WHICH IT WILL RECEIVE UNDISCLOSED SUMS BY NICOX‍​.  Full Article

pSivida Corp reports Q4 loss per share $0.16
Monday, 11 Sep 2017 04:01pm EDT 

Sept 12 (Reuters) - pSivida Corp :pSivida Corp achieves significant milestones throughout fy 2017; reports fourth quarter and fiscal 2017 results.Q4 loss per share $0.16.Q4 revenue $701,000 versus $304,000.Q4 revenue view $467,000 - Thomson Reuters I/B/E/S.Q4 earnings per share view $-0.15 - Thomson Reuters I/B/E/S.  Full Article

pSivida- in connection with new collaboration agreement, Alimera forgave $10 mln of co's share of losses associated with commercialization of ILUVIEN
Monday, 10 Jul 2017 05:40pm EDT 

July 10 (Reuters) - pSivida Corp : :pSivida - in connection with new collaboration agreement, alimera forgave $10 million of co's share of losses associated with commercialization of ILUVIEN.pSivida Corp - Alimera will forgive an additional $5 million of remaining $15 million of previous losses upon approval of iluvien.pSivida - in connection with new collaboration agreement, alimera has right to recover $15 million of such previous losses as partial offset to future royalty payments.pSivida Corp - if amounts recoverable by Alimera are less than $5 million at that time, Alimera will pay company difference in cash.pSivida Corp - has right to recover $15 million of previous losses as a partial offset to future royalty payments.  Full Article

Psivida submits marketing authorization application for approval of Durasert in EU
Thursday, 22 Jun 2017 07:00am EDT 

June 22 (Reuters) - Psivida Corp ::Psivida submits marketing authorization application (maa) for approval of durasert™ three-year treatment for posterior segment uveitis in European Union.Psivida Corp - submitted MAA to EMA, seeking approval to market co's durasert three-year treatment for posterior segment uveitis in European Union.  Full Article

Psivida's Durasert successfully achieves primary efficacy endpoint in second phase 3 study
Tuesday, 13 Jun 2017 07:00am EDT 

June 13 (Reuters) - Psivida Corp :Psivida's Durasert three-year treatment for posterior segment uveitis successfully achieves primary efficacy endpoint in second phase 3 study.Second phase 3 trial of Durasert three-year treatment for posterior segment uveitis achieved trial's primary endpoint.Durasert three-year insert demonstrated a significant reduction in recurrence of posterior segment uveitis through six months.Remain on track to also file a new drug application (NDA) with FDA in calendar Q4 of 2017.Continue to expect submission of European Market Authorization Application (MAA) by end of June for treatment for posterior segment uveitis.  Full Article

Pfizer reports 4.7 pct stake in pSivida Corp as of May 15 - SEC filing
Friday, 26 May 2017 01:45pm EDT 

May 26 (Reuters) - Pfizer Inc ::Pfizer Inc reports 4.7 percent stake in pSivida Corp, as of May 15, 2017 - SEC filing.Pfizer Inc had earlier reported 6.3 percent stake in pSivida Corp as of January 24, 2011.  Full Article

pSivida announces positive 12-month follow-up data for Durasert three-year treatment for posterior segment uveitis
Monday, 8 May 2017 09:15am EDT 

May 8 (Reuters) - Psivida Corp :Psivida corp- durasert™ three-year treatment for posterior segment uveitis significantly reduces recurrences through 12 months.Psivida corp- psivida anticipates reporting top line results from second pivotal phase 3 clinical trial in june 2017.Psivida corp- announced 12-month follow-up data for company's durasert three-year treatment for posterior segment uveitis.  Full Article

Psivida Q3 loss per share $0.15
Thursday, 4 May 2017 04:01pm EDT 

May 4 (Reuters) - Psivida Corp ::Psivida Corp reports fiscal 2017 third quarter results; key milestones on track.Q3 loss per share $0.15.Q3 revenue $590,000 versus $324,000.Q3 earnings per share view $-0.15, revenue view $424000.00 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-HSS And PSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data

* HSS AND PSIVIDA REPORT POSITIVE PHASE 1 KNEE OSTEOARTHRITIS PAIN STUDY DATA